Production of B cell growth factor by a Leu-7+, OK M1+ non-T cell with the features of large granular lymphocytes. by Pistoia, V et al.
0022-1767/85/1345-3179$02.00/0 
Copyright o 1985 by The American Assoclatlon of Immunologists 
THE JOURNAL OF hlMUNOLOZY Voi. 134. No. 5. May 1985 
Printed in U.S.A. 
PRODUCTION OF B CELL GROWTH FACTOR BY A LEU-7+, OKM1+ NON-T 
CELL WITH THE FEATURES OF LARGE GRANULAR LYMPHOCYTES (LGL)' 
VITO PISTOIA,~*+ FEDERICO COZZOLINO,+ MARIA TORCIA,' EMANUELA CASTIGLI,' AND 
MANLIO  FERRARINI'" 
From  the  *Seruizio  di  Immunologia  Clinica,  lstituto  Nazionale  per  la  Ricerca sul Cancro,  Cenova;  the  'Istituto  di  Oncologia. 
Uniuersita di Genova,  Viale  Benedetto XV, 10-16132 Genoua: and  the  ' Is t i tuto di Clinica  Medica 11. Universita di Firenze. 
Viale  Pieraccini. 18-501 39 Firenze.  Italy 
The present  study  reports  the  characterization of 
a non-T cell from  human  peripheral  blood  which is 
capable of releasing BCGF. This BCGF-producing 
non-T cell had a  T3-, T8-, Leu-7+, OKMl+, HLA-DR-, 
Leu-1 1- surface  phenotype  and  was  likely to belong 
to the so-called large granular lymphocyte (LGL) 
subset  because: 1) after  fractionation of non-T cells 
according to the expression of Leu-7 or HLA-DR 
markers,  it  was  found  in  the  Leu-7+, HLA-DR- frac- 
tions that  were  particularly  enriched  in LGL: 2) it 
co-purified  with LGL on Percoll  density  gradients: 
and 3) it  expressed  Leu-7  and OKMl markers  that 
are  shared  by a large  fraction  of LGL. Although  co- 
purified with cells with potent NK capacities,  the 
BCGF-producing cell was not cytotoxic, because 
treatment  of  Leu-7+ cells with  Leu-11  monoclonal 
antibody  and  complement  abolished  the NK activity 
but left the BCGF activity unaltered. The factor 
released by this LGL subset was not IL 1 or IL 2 
mistakenly interpreted as BCGF. because: a) cell 
supernatants  particularly  rich  in BCGF activity  con- 
tained  very little or no IL 1 or IL 2; b)  BCGF-induced 
B cell proliferation  was  not  inhibitable  by  anti-Tac 
antibodies (this in spite of the  expression of IL 2 
receptor  by a proportion  of  activated B cells): and c) 
BCGF activity was  absorbed  by B but  not T blasts. 
Proliferation and differentiation of B lymphocytes into 
plasma cells is a complex multistep process that is, in 
part,  under  the  control of T cells (as reviewed in Refer- 
ences 1-3). Such control is exerted by direct cell-cell 
interaction (4, 5) or  through  the release of a number of 
soluble factors (6-9). Of these  factors, B cell growth factor 
(BCGF),3 which supports cell proliferation, and B cell 
differentiation  factor,  which  induces  transformation of 
lymphocytes into plasma cells, are probably the most 
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widely studied. Both factors  are active on cells activated 
by contact  with  antigen (or other ligands in vitro),  but 
have  no effect on resting B cells. Although it is now clear 
that  these factors are released by T cells, it is not known 
whether or not they can be produced also by other cells. 
In human peripheral blood, most of the  natural killing 
(NK) activity is mediated by the so-called large granular 
lymphocytes (LGL) (10-12). Besides  cytotoxic properties, 
LGL have been shown to participate in the regulation of 
the proliferation of other cell types  (1 3- 16). a  finding that 
is consistent with other  data from animal models dem- 
onstrating  similar  functions  for NK cells (17-21).  This 
regulatory control can be exerted by an apparently direct 
cytotoxic effect on proliferating cells or through the 
release of soluble factors. Of particular note in this con- 
nection is the finding that defined LGL subsets can 
release lymphokines such as burst-promoting activity 
(BPA), IL 1, IL 2, or colony-stimulating  factor (1  5, 22,  23). 
In the  present  study, we investigated the capacity of 
human peripheral blood non-T cells of releasing BCGF. 
We found that a non-T cell with LGL characteristics 
which expresses the OKMl and Leu-7 markers,  but dis- 
plays very little or no NK activity, can release BCGF. 
MATERIALS AND METHODS 
obtained from the plateletpheresis of 300 to  500 ml of blood and 
Cellfractionatton  procedures. Leukocyte-rich buffy coats were 
mononuclear  cells (MNC) separated on Ficoll-Hypaque (F-H) density 
gradients. Monocytes were removed by adherence on plastic petri 
dishes  (24). T  cells were separated from adherent cell-depleted MNC 
by rosetting  with neuraminidase-treated  sheep erythrocytes (E), fol- 
lowed by fractionation on two subsequent F-H density  gradients  (24). 
Sheep E were removed from rosetting cells (T cells) by hypotonic 
lysis (24). Nonrosetting cells (non-T cells) were re-rosetted and were 
depleted of the  remaining T cells through  another F-H gradient (24). 
nants were  detected by rosetting with ox E coated with the PTF 291 
Cells that expressed surface HLA-DR antigens or Leu-7 determi- 
tively. PTF 29/12  was a generous gift of Dr. G. Damiani (25).  The 
12 anti-HLA-DR monoclonal antibody or the Leu-7 reagent, respec- 
clone producing Leu-7 (HNK-1) antibody, originally raised by Abo 
and Balch (26, 27). was obtained from the American Type Culture 
Collection (Rockville. MD). These murine monoclonal antibodies 
were purified from ascitic  fluids on a Sephadex  G-200  column, were 
dialyzed against  saline.  and were coupled to ox E, according to the 
technique of Ling et al. (28). Cells were rosetted a t  4°C and  rosettes 
were separated  on F-H density  gradients. 
In all of the above experiments. the rosette-enriched fractions 
contained a minlmum of 94% rosetting  cells and  the rosette-depleted 
fractions never had more than 4% rosettes. Non-T cells  never  con- 
tained more than 3% T cells, as assessed by staining with OKT3 
monoclonal (see below). T  cells  never  contained more than 2% cells 
with surface immunoglobulin (sIg) or HLA-DR antigens. 
LGL were isolated from adherent cell-depleted MNC on a discon- 
tinuous Percoll density  gradient, as  reported previously (12). In brief, 
seven different Percoll concentrations (in 2-mI aliquots). ranging 
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from 40  to 55% and  each differing from the  next by 2.5%. were 
layered  in 15-1111 conical test  tubes,  starting from the solution with 
the  highest density. Cells (5 x lo7) were layered on  the top of the 
gradient  and were centrifuged at  550 x G for 30 min.  Fractions 2 
and 3, which contained  the highest  proportion of LGL as assessed 
by morphology, cytochemistry. and surface marker analysis (see 
below), were pooled. To remove any  remaining T cells, LGL were 
subsequently depleted of E rosettes as described  above. 
a rosette  technique as detailed previously (24). Cells with sIg were 
Cell phenotype analysis. Cells with E receptors were  detected by 
detected by staining  with a rabbit  F(ab')z  anti-human Ig (polyvalent) 
serum conjugated with  fluorescein  isothiocyanate (FITC) (29). Mouse 
monoclonal antibodies  to  human MNC were  obtained  from different 
sources. Anti-T cell reagents (OKT3. OKT4. and OKT8) were  from 
Ortho  Pharmaceutical Corp. (Raritan. NJ) .  Anti-HLA-DR antibodies 
(HLA-DR or PTF 29/12) were from Becton Dickinson, Sunnyvale, 
CA. and from Dr. G. Damiani. respectively. An anti-monocyte/mac- 
rophage monoclonal reagent which also  stains NK cells (OKM1) was 
purchased from  Ortho Pharmaceutical Corp. An anti-B cell mono- 
clonal  antibody (Bl)  was obtained  from  Coulter  Electronics  (Hialeah, 
FL). Two LGL-specific monoclonal antibodies were used, namely 
Leu-7  (HNKl),  described above. and Leu-1 1 b, which was  purchased 
from Becton Dickinson. All of the above reagents were used in 
indirect  immunofluorescence with a n  FITC-conjugated rabbit F(ab'), 
anti-mouse Ig (polyvalent). Preparations were  observed under a Leitz 
was calculated on  counts of a minimum of 200 cells per preparation. 
Orthoplan fluorescence microscope. The percent of positive cells 
LGL were  identified by staining  with Giemsa or for  the cytochem- 
ical localization of acid a-naphthyl  esterase  or acid phosphatase a s  
reported previously (1 1). In the  preparations  stained  for  these  en- 
zyme activities, LGL display a paranuclear  staining  pattern. T  cells 
show a  dot-like staining,  and monocytes show a diffuse  staining: B 
cells are  unstained. 
Cytotoxicity assays. Cell cytotoxicity with monoclonal antibodies 
and complement was  carried  out as detailed previously (15). In brief, 
cells  were suspended at  a concentration of 1 x 107/ml in RPMI 1640 
medium (GlBCO-Biocult, Glasgow, Scotland]  which contained OKT3 
or OKT8 (both at  a final dilution of 1/100). OKMl (at a final dilution 
of 1/20),  or Leu-1 1 (at a final dilution of 1/50) monoclonal antibodies 
or no antibody (control). After a 1-hr incubation on ice, nontoxic 
rabbit complement (Pel-Freeze, Rogers, AR) was added a t  a final 
dilution of 1/2  in RPMl 1640.  The cells were incubated  at 37OC for 
and were incubated again at  room temperature for 30  min. Dead 
1 hr. were washed twice, were resuspended in fresh complement, 
gradients. When this procedure was  not feasible.  owing to  the  small 
cells  were removed by centrifugation of the cell suspension  on F-H 
cell numbers obtained, dead cells were detected by trypan blue 
staining and were excluded from the counts carried out for the 
determination of cell concentration. To assess the efficiency of 
complement-mediated cytolysis, the proportion of dead  cells in  the 
suspensions  treated  with a given monoclonal antibody was  deter- 
compared to that of the cells stained by the same antibody in 
mined by staining  with  trypan blue or aethidium bromide. and  was 
immunofluorescence. 
least 80% of the cells that  stained  in immunofluorescence. 
In the preparations used, complement-mediated lysis killed at  
51Cr-labeled K562 cells (30). In brief, 4 X lo6 K562 cells were 
NK activity was  measured  in a conventional 4-hr assay against 
incubated with 100 pCi  5'Cr (Na, 51Cr04: Amersham, Arlington 
Heights, IL) in 1 ml of Hanks'  balanced  salt solution (HBSS) for  60 
min at  37°C. were washed four times, and were resuspended in 
HBSS-FCS. Different effector to target (E:T) ratios were selected, 
ranging from 40:l  up  to  0.6:l. E:T mixtures were incubated  for 4 
hr. were  centrifuged, and  the  supernatants were recovered and were 
counted. Maximal release was determined by lysis of labeled K562 
cells  with 0.1 N HCl. The percentage cytotoxfclty was calculated as 
follows: 
% c x  = 
Exp - Sp 
Max - Sp x 100 
where  Exp is radioactivity  release  induced by effector  cells, Sp is 
radioactivity spontaneously released by %r-labeled K562 cells, and 
Max is radioactivity  released by HC1-lysed K562 cells. 
Alternatively, results were  expressed as lytic units (LU)/107 cells: 
1 LU is defined as the  number of the effector  cells  required to release 
10% specific radioactivity. This calculation gives a good comparison 
experiments  against  the  same  targets, providing that  the  slopes of 
of the cytotoxicity activity of effector  populations tested in the  same 
the dose-response curves  are  similar. 
Preparation of culture supernatants. Different cell fractions 
were cultured at   the  concentration of 1 X 10" cells/ml in RPMl 1640 
containing  10% FCS in 24-well plates  for  48  hr. Phytohemagglutinin 
(PHA-P:  Difco, Detroit, M1) was included in  culture media at  the  final 
concentration of 1 pl/ml. All supernatants were collected subse- 
quently  and were  stored at  -20°C. 
IL 2-enriched supernatants. Lymphocyte-conditioned medium 
(Ly-CM) enriched with IL 2 was obtained by stimulating normal 
peripheral blood MNC with 1 pl/ml PHA-P. After 40  hr,  Supernatants 
were recovered, were aliquoted. and were  stored at  -20°C until use. 
Lymphokine assays: BCGF assay. Surgically removed tonsils 
were minced with a fine needle and MNC were isolated on F-H density 
gradients (29). T cells were removed by E rosetting as described 
above. Non-T cells were  re-rosetted  with  E and were depleted of the 
tionated  on a Percoll density  gradient as follows (31). Cells (5 X 10') 
remaining T cells  on another F-H gradient. Non-T cells  were frac- 
were resuspended  in 2 ml of 100% Percoll solution in a 15-1111 conical 
test  tube. Four additional Percoll concentrations (diluted in RPMI 
1640 supplemented with 10% FCS). 60. 50, 40. and 30%. were 
layered over the  100%  fraction  starting from the bottom of the  tube. 
Cells were spun at 3000 rpm in a tabletop centrifuge. Four cell 
fractions were  obtained: the  first contained low density cells. pre- 
dominantly  constituted by large  B  cells and monocytes, whereas  the 
fourth  band  was highly enriched  for small  restingB cells. The second 
and  the  third cell fractions comprised cells of intermediate  charac- 
teristics. High density cells from fraction 4 were collected, were 
washed  twice, and were stimulated at  the  concentration of 1 x 10" 
cells/ml in  culture medium for 3 days  with killed Staphylococcus 
aureus of the I Cowan strain (SAC) (kindly  donated by Dr. S .  Rom- 
agnani). SAC-activated B  cells  were  washed subsequently  and were 
cultured  for an additional 3 days  in 96-well, flat-bottomed plates (5 
x lo4 cells/well) in  the presence or absence of the  different  super- 
natants  to be tested. At the  end of this time,  cells  were pulsed with 
1 pCi of (3H]thymidine for 8 hr. were harvested,  and were  counted. 
In some experiments, BCGF assays were performed in  the presence 
of anti-Tac monoclonal antibody (32) (kindly provided by Dr. T. 
Waldmann)  that Identifies IL 2  receptor. This  reagent  was included 
in  the  culture medium a t  time 0. using a final dilution of 1/1000. 
IL 2 assay. IL 2 activity was  measured by determining  the capacity 
of the following cells to be stimulated:  1) a PHA-induced normal  T 
cell line  that  had been expanded  and kept in  culture  for 2  mo by 
adding exogeneous IL 2: this  line  was  unresponsive  to PHA in the 
absence of any added  irradiated  accessory cell; and  2)  the  murine 
cell line CTLL-2 (33). 
Human T blasts or CTLL cells were washed twice, were resus- 
pended in RPMI 1640  containing  10% FCS, and were  cultured for 
24  hr  in 96-well,  flat-bottomed plates at  the  concentration of 2 X 
104/well for human T  cells or 1 X 104/well for CTLL, in  the presence 
or absence of various dilutions of the  supernatants  to be tested. At 
the  end of this time,  cells  were  pulsed and were processed as de- 
scribed  above. Results obtained in  the two different experimental 
systems were completely overlapping. 
IL 1 assay. 1L 1  activity was assayed by using  the conventional 
thymocyte assay  (34). In brief,  thymocytes, recovered from  surgically 
well, flat-bottomed plates at  the  concentration of 1.5 x 106/well. in 
removed thymuses of C3H/HeJ mice, were  cultured  for 72  hr in 96- 
the presence of PHA-P (1 pl/ml) alone or of  PHA plus  serial dilutions 
of the  supernatants  to be tested.  Subsequently,  the cells  were proc- 
essed as described above. One  unit of IL 1 was defined as the  amount 
of supernatants capable of doubling the [3H]thymidine incorporation 
by 1.5 x 10" PHA-stimulated thymocytes. 
formed as follows. Selected supernatants were subdivided into two 
Absorption experiments. Absorption experiments were  per- 
aliquots. The  first  was used as a control (unabsorbed  supernatant). 
whereas 2 ml of the second one were incubated for  4 hr  at 4°C with 
4 x lo' B blasts, generated by a 3-day stimulation with SAC, or 
equal numbers of T blasts, obtained by PHA stimulation of periph- 
eral blood MNC for 48 hr. At the end of the incubation period. 
absorbed supernatants were recovered by centrifugation and were 
tested  in parallel with  the control supernatants. 
RESULTS 
BCGF productton by non-T cells. Unfractionated MNC, 
T cells, and non-T  cells were  pulsed with PHA for 48 hr. 
T cells (that contained 1 to 2% contaminant monocytes) 
proliferated vigorously, as judged by light microscopy, 
whereas occasional blasts were seen in the non-T cells. 
When stimulated with PHA, all cell fractions produced 
BCGF (Fig. 1). whereas no BCGF was released in the 
absence of PHA. Furthermore, PHA alone at the concen- 
tration used failed to  sustain  the proliferation of SAC- 
stimulated cells (data not shown]. In three experiments, 
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Figure 1 .  BCGF production by unfractionated MNC and non-T cells. 
The results represent the mean f SE of three experiments. 
TABLE I 
Surface phenotype of SAC-stimulated tonsil non-T  cells 
Surface Marker 
% Positive 
Cells' 
97.5 f 1 . 1  
B1 
91.2 f 2.7 
Tac 
79.5 f 5.7 
OKT3 
13.0 f 3.1 
3.3 f 1 . 1  
OKM 1 4.4 f 0.3 
Leu-7 1.4 f 0.9 
the square root of the pooled variance divided  by the overall number of 
a Mean f SE from three different experiments. The SE is calculated as 
samples. The homogeneity of variance between experiments was dem- 
onstrated and no significant differences between the means were docu- 
mented. 
HLA-DR 
SIg 
non-T cells were treated  with OKT3 antibody and com- 
plement to remove any remaining T cells. After this 
treatment,  the BCGF titration  curve  was  unchanged  (data 
not shown). 
Tonsil B cells were fractionated  on Percoll gradients  to 
remove large (probably  pre-activated  in vivo) B cells that 
proliferated spontaneously in vitro (35). Surface  marker 
analysis demonstrated that  the vast majority of SAC- 
stimulated cells were B cells, with  a negligible contami- 
nation of T cells (Table I). This control  was  necessary  to 
ensure  that  the major target of the  factors contained in 
the  supernatants tested were indeed B cells. 
Characterization of the non-T cells that produce 
BCGF. Non-T cells were separated into HLA-DR- and 
HLA-DR+ cells, and the two fractions were tested for 
BCGF production. BCGF activity was detected in the HLA- 
DR- cell supernatants only,  in amounts  that were some- 
what higher than those  found in the unfractionated  non- 
T cells (Fig. 2). Dilutions of 1/4 or 1/8 of the HLA-DR- 
cell supernatants were more efficient in sustaining B cell 
proliferation than  the  1/2 dilution, a finding that may 
suggest the presence of small  quantities of a lymphokine 
with  inhibitory  properties.  Table I1 shows  the phenotype 
of HLA-DR- cells together with that of the other cell 
fractions used in the present experiments. The large 
majority of HLA-DR- cells were OKMl+,  Leu-7+, and Leu- 
11 +. Cells identifiable as B cells or monocytes were less 
than 2%. Likewise, as  reported previously (1 5). there were 
no cells with  T cell markers, except for a  subset of cells 
expressing the OKT8 marker. 
112 114 118 1/16 
SUPERNATANT MWTK*IS 
Figure 2. BCGF production by different non-T cell subsets. The results 
represent the mean f SE of five experiments. 
The  finding of a high proportion of Leu-7+ cells in  the 
HLA-DR- fraction prompted experiments in which Leu- 
7+ cells were isolated from non-T cells and were tested 
for BCGF production. Most of these cells had morphologic 
features  and  surface  markers of LGL (Table 11). and re- 
leased BCGF in a  quantity  comparable to that of HLA- 
DR- cells (Fig. 2). In contrast, Leu-7- cells released very 
little or no BCGF (Fig. 2). Comparative analysis of the 
properties of  HLA-DR- non-T cells and Leu-7+ cells 
showed that they comprised LGL with  similar  phenotype, 
with the exception that Leu-7+ cells also contained a 
number of HLA-DR+ cells. Furthermore, HLA-DR- cells 
had  a  much higher NK activity than Leu-7+ cells (Table 
11). a  finding which is also corroborated by the observation 
that non-T cells depleted of Leu-7+ cells (Leu-7- cells) 
retained a high cytotoxic activity (Table 11). 
In another  series of experiments, LGL were prepared 
on Percoll density gradients. These fractions were en- 
riched in cells with Leu-7 and Leu-1 1  markers,  and dis- 
played a potent NK activity (Table 11). When tested for 
BCGF, they were found to produce BCGF in amounts 
comparable  to  those of HLA-DR- and Leu-7+ cells (Fig. 
The  surface phenotype of the BCGF-producing  cell was 
studied further in the following experiments. Leu-7+ cells 
were treated with Leu- 1 1, OKT8, and OKMl monoclonal 
antibodies and complement or with complement alone 
(control).  The cells were tested for NK activity and BCGF 
production. As  apparent from Figure 3, treatment with 
OKMl monoclonal antibody largely decreased BCGF pro- 
duction and NK function.  Treatment  with Leu-1 1 mono- 
clonal almost abolished the cytotoxic activity,  but did not 
influence BCGF production. Treatment  with OKT8 had 
no effect on both functions.  The  same  data were obtained 
by treating Percoll-purified LGL with the  same monoclon- 
als and complement (data not shown). Together, the 
above data show that BCGF was released by an OKMl+, 
Leu-7+, Leu-1 1- LGL with very little or no NK activity. 
Furthermore,  the  data confirm that most NK activity is 
in the Leu-1 1+  cells, and  that  the cytotoxicity found  in 
the Leu-7'  cell fractions is mainly  attributable  to  the cells 
also  expressing the Leu-1 1  determinant (36, 37). 
HLA-DR- non-T  cells d o  not  produce IL 1 or IL 2. All 
cell fractions  that released BCGF were tested for their 
2). 
capacity of producing IL 1, because IL 1 may be involved 
- in  the control of B cell proliferation (3, 38). The simulta- 
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TABLE I1 
Characterlstfcs of the drtferent non-T cell  subpopulations  used 
" 
Surface Marker 
OKMl 
Leu-7 
OKT3 
Leu- 1  1 
OKT4 
OKT8 
E 
HLA-DR 
s1g 
Cytochemical markersa.d 
HLA-DR. 
Cellsa Leu-7+ Cells" 
70f 7 
73 -t 5 
78 f 7 
<2 
<2 
1 4 %  2 
<2 
<2 
<2 
83f 4 
92 f 4' 
5 1 f  6 
(2 
<2 
<2 
<2 
2 8 f  3 
7f 2 
Percoll-purlfled 
L G L ~ . ~  
70 f 5 
65 f 8 
<2 
73 -t 5 
<2 
11 f 3 
<2 
(2 
<2 
HLA-DR+ 
Cellsa 
46f  6 
14-t 3 
1 2  
<2 
1 2  
1o-t 4 
<2 
4 9 f  4 
93 f 6' 
Leu-7- Cellsa 
53 f 4 
<2 
39-t 4 
e 2  
<2 
1 2  
5 f  3 
47 f 5 
70 f 8 
Acid hydrolases: 
2) dot-like (T  cells) 
11 paranuclear (LGL) 91 f 8 9 3 f  5 85f 10 I O +  3 
<2 <2 
ND' 
31 diffuse (monocytes) <2 
<2 
<2 
ND 
41 negative (B cells) <2 
5 f  2 29f  3 
<2 
ND 
4-t  1 6 0 f  8 ND 
<2 
NK activity' 908 f 150  310 50 9 5 4 f 1 0 3  8 0 %  10 12402160 
Mean percentage of posltive cells f SE from  three  dlfferent  experlments. 
Fractions 2 and 3 from Percoll gradlents  were pooled and were depleted of cells  formlng  E  rosettes. 
Detected by rosettlng  during  the  separatlon  procedures. 
See  Materlals and Methods for details  on  criteria of cell identification  according  to  their  staining  pattern. 
e ND, Not done. 
'The results  are  expressed as LU calculated at  10% specific lysis per lo' effector cells [mean + SE of three  dlfferent 
experiments). 
l a  
40 20 M 5 2.5 1.2 
EFFECTOR I TARGET R A T 0  
1R 1 I4 li8 126 
SUPERNATANT DILUTIONS 
Figure 3. Leu-7+  non-T  cells were treated  with OKT8, OKM 1, and Leu- 
1 1 b monoclonal antibodies. and were  tested  for NK actlvlty (a]. The  same 
supernatants were tested for BCGF activity (b] .  a. The results of one 
cell suspenslons were also stimulated with PHA for 48 hr. and the 
representative  experiment of the  four  performed.  The  results  reported In 
b represent  the  mean f SE of the  same  four  experiments.  The  results 
obtained  after  treatment  with  complement  alone  were  superlmposable  to 
those  obtained  with OKT8 plus  complement  (and  hence  not  reported). 
neous  presence of the two lymphokines could raise  the 
problem of how much of the B cell proliferation observed 
was due to IL 1. HLA-DR- cells consistently failed to 
produce IL 1, yet their  supernatants  had a vigorous BCGF 
activity (Table 111 and Fig. 2). In contrast, HLA-DR+ and 
Leu-7- cells, which produced consistently more than 90 
U/ml of IL 1, never released BCGF (Fig. 2). Leu-7' cells 
released variable,  but  sometimes abundant,  amounts of 
IL 1 (Table 111). Recently, it has been reported that a  subset 
of  HLA-DR+  LGL release IL 1 (23).  The Leu-7+ cells tested 
here contained variable proportions of HLA-DR+ cells 
(Table 11); therefore, the  data on IL 1 production are not 
unexpected. 
Non-T  cell fractions were also  tested  for IL 2 produc- 
tion. Again, HLA-DR- cells consistently failed to release 
IL 2,  whereas  small  amounts of IL 2 were produced by 
Leu-7+ cells (Table 111). However, both fractions  had  the 
same capacity of releasing BCGF. A proportion of SAC- 
activated  B cells expressed IL 2  receptors,  detectable by 
staining  with  anti-Tac monoclonal antibody (Table I and 
Reference 39). Because activated  B cells can proliferate 
in  response to IL 2 (39), this finding  warranted  further 
studies on the role possibly played  by IL 2 in our  system. 
SAC-activated B cells were cultured with HLA-DR- or 
Leu-7+ cell supernatants in the presence  or absence of 
anti-Tac monoclonal. In these  cultures,  the proliferative 
response to Leu-7+ cell supernatants decreased only mar- 
ginally. and  that to HLA-DR- cell supernatants did not 
change at all (Fig. 4). These  findings further confirm that 
B cell proliferation was  not  due  to 1L 2. Treatment  with 
anti-TAC monoclonal antibody  inhibited the proliferation 
of PHA-induced T blasts to IL 2-rich Ly-CM (data not 
shown). 
The  supernatants of HLA-DR- or Leu-7+ cells were also 
absorbed  with SAC-activated B cells or PHA-activated T 
cells before being tested for BCGF activity. BCGF was 
absorbed by B but not T  blasts (Fig. 4). 
DISCUSSION 
The  present  study  demonstrates BCGF production by a 
non-T cell from human  peripheral blood. BCGF was de- 
BCGF PRODUCTION BY LGL 
TABLE 111 
IL 1 and IL 2 production by dltferent non-T cellfractions 
IL 1 Activity 
U/ml 
[3Hlthyrnldine lncorporatlon 
1L 2 Actlvlty 
CPm Supernatants 
Expt. 1 Expt. 2 Expt. 3 Expt. 1 Expt. 2 _ _ _ ~  Expt. 3 
Leu-7+ cells" and  supernatantsb 18 33  28  4.156f  616,7682 308  3.261 f 284 
HLA-DR- cells"  andsupernatantsb 1 2  <2 <2 2,084 f 167 1.597f 197 1,638 f 196 
Macrophage supernatant' 67 94  75 ND  ND  ND
Medium 
Ly-CM' ND" ND  ND 38.824 f 1.427 42.382 f 2.127 41,225 f 1.981 
- 1,824 f 98  1,683 2 286  1,427 f 124 - - 
Fractionated cells [ 1 x 1 Oa) were cultured for 48 hr with 1 p g m l  PHA-P. 
Supernatants were tested  at  different  dilutions, and the reported values are relative to those yielding the highest IL 2 
activity. 
were used  at 1/32 dilution. 
IL 2-enriched  supernatants were obtained by  PHA-P stimulation of  MNC. as described in Materials  and  Methods.  and 
ND.  Not determined. 
'Peripheral blood adherent cells. detached from plastic. were cultured at 1 X lo6 cells/ml with 1 rglml PHA-P for 48 
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Figure 4. Upper section: percentage reduction of BCGF activity pres- 
ent in HLA-DR- (.) and Leu-7+ (01 cell  supernatants  after absorption on 
SAC-generated B cell blasts and PHA-activated T  cell  blasts.  The  results 
represent the  mean t SE of three experiments. Lower section: percentage 
reduction of BCGF activity present in HLA-DR- (.) and Leu-7+ ( 0 )  cell 
supernatants  when tested on SAC-activated B cell blasts in the presence 
of anti-Tac monoclonal antibody. The  results represent the  mean f SE of 
three experiments. 
tected in supernatants of suspensions depleted of T cells 
by E rosetting and monoclonal antibody  treatment.  This 
finding,  together  with the observation that  the  titration 
curve of BCGF production was similar for T and non-T 
cells, excludes the possibility that T cells contaminating 
the  non-T  suspensions could be responsible for the re- 
sults obtained. 
The BCGF-producing  cell was likely to  be an LGL be- 
cause it was found in LGL-enriched cell fractions, co- 
purified with LGL on Percoll density  gradients  and, like 
a  large number of LGL, expressed the OKMl and Leu-7 
markers.  This BCGF-producing  cell was, however, incap- 
able of NK activity. This conclusion is based on the 
results of the  experiments in which treatment of Leu-7+ 
cells with Leu-1 1 monoclonal and complement failed to 
inhibit BCGF production and yet inhibited cell cytotoxic- 
ity. Furthermore,  the observation that Leu-7-cells (which 
contained  approximately 40% Leu-1 1+ cells) had  a high 
NK activity but did not produce BCGF reinforces the 
concept that NK activity and BCGF production may be 
functions of different cells. LGL are heterogeneous and 
include cytotoxic cells together  with  other cells with dif- 
ferent  functions. A number of specialized LGL subsets 
can be identified through the expression of different 
surface  markers. For example, LGL that produce IL 1 are 
HLA-DR+, M1+, B.73.1+ (23), those that produce IL 2 are 
HLA-DR+, T1 I +  (22). and those that release BPA are HLA- 
DR-, M I + ,  Leu-1 I+, Leu-7+ (15). The BCGF-producing 
cell with  a Leu-7'. M1+, HLA-DR-, E-, Leu-1 I-, T3- phe- 
notype seems to belong to an LGL subset  different from 
all of the above. The  finding of a  marked heterogeneity 
of phenotypes and  functions  makes it increasingly diffi- 
cult to solve the problem of whether or not LGL are cells 
from a single lineage which specialize in different  func- 
tions  during  their  maturation. Alternatively, that of LGL 
could be an operational definition to indicate  granulated 
cells, possibly from different lineages, which share a 
number of properties. 
A particular  issue to be discussed here is represented 
by the role possibly played by IL 1 or IL 2 in  our experi- 
ments. Previously, it was proposed that IL 1 can be in- 
volved in sustaining  the growth of preactivated B cells (3, 
38). A number of observations exclude that the BCGF 
activity measured in our  experimental  system could be 
attributable  to IL 1.  First,  the  supernatants of HLA-DR- 
cells, which were rich in BCGF activity,  contained very 
little or no IL 1. Second, IL 1 -rich supernatants,  such as 
those of HLA-DR+ cells, failed to promote B cell growth. 
Third, as mentioned above, the  surface phenotype of the 
BCGF-producing cell is different from that of IL l-pro- 
ducing LGL and  that of monocytes. Finally, it is perhaps 
worth noting that, in most experimental systems, IL 1 
cooperates with,  rather  than  substituting  for, BCGF (3, 
38). The possibility that IL 2 was responsible for the 
growth of SAC-activated B cells (that  express IL 2 recep- 
tors)  was ruled out by the following observations.  First, 
Leu-7+ only (and not HLA-DR- cells) released small 
amounts of IL 2, yet the  supernatants of the two cell 
fractions  had  comparable BCGF activity. Incidentally, the 
finding that Leu-7' but  not HLA-DR- cells released IL 2 
was not unexpected in  consideration of the phenotype of 
IL 2-producing LGL (22). Second, anti-Tac monoclonal 
antibody failed to  inhibit B cell proliferation induced by 
HLA-DR- cell supernatants  and inhibited only marginally 
that induced by the  supernatants of Leu-7+ cells. Third, 
the BCGF activity of both HLA-DR- and Leu-7+ cell su- 
pernatants  was absorbed by B but not T blasts. 
At present, it cannot  be decided whether BCGF released 
by LGL is identical to that produced by T cells or else 
3184 BCGF PRODUCTION BY  LGL 
represents a different  interleukin  with  similar  functions. tivity on human peripheral blood burst forming units, 
Unfortunately, the  number of cells obtained in each ex- 
natants in amounts  sufficient  for a chemical analysis of tion: enhancing effect of large granular lymphocytes. ~ x p .  Hernatol. 
continuous  cultures may be of help  to solve this problem, 
although of the various  lines we have so far obtained, 
engage in regulated reaction against self to ensure homeostasis? 
lrnrnunol. Rev. 44: 13. 
very few have an OKM1+~ Leu-7+ surface phenotype* and for the involvement of natural killer cells in bone marrow transplan- 
18. Lotzova, E., S. B. Pollack. and C. A. Savary. 1982.  3irect  evidence 
this is not always  a stable  one. tation. In NK Cells and  Other  Natural Effector Cells. R. 8. Herber- 
a number Of functions On the pro- 19. Kiessling, R., P. S. Hochman, 0. Haller, G. N. Schearer, H. Wigzell, 
liferation of other cell types  have been attributed  to  var- and G. Cudkowicz. 1977. Evidence for a similar common mechanism 
ious subsets of human L ~ L .  These cells can promote 5)  for natural killer activity and resistance to hemopoietic grafts. Eur. 
or  inhibit (1 4, 19) hemopoiesis, depending on the differ- 20. Riccardi. C., A. Santoni, T. Barlozzari, and R. B. Herberman. 1981. 
ent experimental conditions used; they can also regulate In vivo reactivity of mouse natural killer (NK) cells against normal 
T lymphocyte proliferation (16)  and inhibit Ig production 21. Warner, J. F., and G. Denned. 1982. Effects of a cloned cell line 
in vitro (40, 41 1. The demonstration of the capacity of with NK activity on bone marrow transplants. tumour development 
releasing BCGF adds  further weight to the regulatory role 22. Kasahara. T.. J. Y. Djeu, s. F. Dougherty, and J. J. Oppenheim. and  metastasis in vivo. Nature  300:31. 
of LGL. 
multiple  lymphokines:  interleukin-2,  interferon  and colony stimulat- 
1983. Capacity of human large granular lymphocytes to produce 
ing  factor. J .  Irnmunol. 131:2379. 
Herberman, and J. J. Oppenheim. 1984. Human large granular 
Strada for the  continuous  supply of normal blood sam- lymphocytes are potent producers of interleukin- 1. Nature 309~56. 
pies; Dr. G. Damiani for the gift of the P ~ F  29/12 anti- 24. Moretta. L.. M. Ferrarini. and M. D. Cooper. 1978. Characterization 
of human  T cell subpopulations as defined by specific  receptors for 
HLA-DR monoclonal antibody; Dr. S .  Romagnani for hav- immunoglobulins.  Contemp. Top. Irnmunoblol. 8:27. 
Dr. T. H. Waldman for the generous gift of the  anti-Tac 
Analysis of  HLA-DR polymorphism by two dimensional  peptide  map- 
ping. Proc. Natl. Acad.  Sci. USA 78~534. 
monoclonal antibody. we are indebted to M ~ .  Susanna 26. Abo, T.. M. D. Cooper. and C. M. Balch. 1982. Postnatal expansion 
of the  natural killer and killer cell populations in humans identified 
Caprile for secretarial help. by the monoclonal HNK-1 antibody. J. Exp. Med. 155:321. 
27. Abo. T.. and C. M. Balch. 1981. A differentiation  antiaen of human 
Ferrarini. 1985. Large granular  lymphocytes  have a promoting ac- 
periment  was too small  to allow the preparation of super- 16. PiStOia, v., A. Nocera, R. Ghio, A. Leprini. A. Perata, M. Pistone, 
Blood. I n  press. 
and M. Ferrarini. 1983. PHA-induced human T-cell colony forma- 
the factor' Studies with LGL lines Or 'lone' expanded in 17. Cudkowicz, G., and P. S. Hochman. 1979. Do natural killer cells 
11:251. 
man.  ed. Academic Press. New York. P.  1535. 
J. Imrnunol. 7~655. 
bone  marrow cells. Cell. Irnmunol. 60: 136. 
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